Uncategorized

GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug

Published

on

Jideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer assets in late-stage development.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version